A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS)

Summary

This study aims to evaluate the safety, tolerability and PK of repeat dose administration of GSK2618960 in the treatment of pSS. The study will contain two parts, Part I will be open label and Part II will be randomized, double-blind. The minimum duration of Part I \& Part II of the study will be 26 and 32 weeks respectively.

Timeline

Start

2017-09-19

Primary completion

2017-10-12

Completion

2017-10-12

Outcome

Outcome not reported

Stopped (Business): “The study is stopped for Portfolio prioritization.”

Drugs

Indications